SUSTOL—proven 5-day CINV protection to smooth the journey

SUSTOL is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens.

  • Unique formulation provides a sustained release of granisetron that offers protection that lasts for ≥5 days1,2
  • The only 5-HT3 RA to demonstrate superiority in a Phase 3, 3-drug vs 3-drug HEC trial3
  • Unscheduled mean CINV-related hydration rate was lower for SUSTOL than for palonosetron in 2 real-world retrospective studies4,5
  • Robust safety profile in clinical studies involving >2400 patients1,6,7
SUSTOL is an NCCN Category 1 Recommended Option

Granisetron extended-release injection (SUSTOL) is a Category 1 option in the NCCN Guidelines® for the prevention of acute and delayed emesis due to HEC and MEC.*†‡§

Granisetron extended-release injection (SUSTOL) is also a preferred option in MEC when used in a combination with dexamethasone in a 2-drug antiemetic regimen.8∥

  • When used in recommended antiemetic combination regimens on day 1.
  • NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Antiemesis.
  • Category 1: Based upon high-level evidence, there is uniform National Comprehensive Cancer Network® (NCCN) consensus that the intervention is appropriate.
  • SUSTOL is indicated for the prevention of CINV due to MEC and AC combination chemotherapy.
  • See the NCCN Guidelines for detailed recommendations, including other preferred options.
5-HT3 RA=5-hydroxytryptamine receptor antagonist; AC=anthracycline/cyclophosphamide; CINV=chemotherapy-induced nausea and vomiting; HEC=highly emetogenic chemotherapy; MEC=moderately emetogenic chemotherapy; PK=pharmacokinetics.

References:

  1. SUSTOL [prescribing information]. Heron Therapeutics, Inc., 2017.
  2. Ottoboni et al. J Exp Pharmacol. 2014.
  3. Schnadig et al. Future Oncol. 2016.
  4. Vacirca et al. Future Oncol. 2018.
  5. Erickson et al. Future Oncol. 2019.
  6. Data on File [C2006-01]. Heron Therapeutics, Inc.
  7. Gabrail et al. Cancer Manag Res. 2015.
  8. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Antiemesis V.1.2022. ©National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed February 15, 2022. To view the most recent and complete version of the guideline, go to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  9. Zhou et al. Ther Clin Risk Manag. 2015.